Novo Nordisk is expanding its operations in India due to the high demand for its weight-loss drug, Wegovy, and diabetes treatment, Ozempic.
The company plans to double the number of global process leaders in India over the next few years. This expansion is part of a broader initiative to strengthen senior leadership and operational capabilities in Bengaluru.
Novo Nordisk aims to increase its overall workforce in India by 16% and has formed partnerships with ten Indian AI start-ups to enhance efficiency. The integration of AI tools has significantly reduced the time required for quality checks on essential documents.
Novo Nordisk envisions its India center becoming similar to its headquarters in Denmark, particularly in handling research and development data. This strategic move aligns with the trend of pharmaceutical companies expanding their operations in India.
Novo Nordisk is also preparing to compete in the growing global weight-loss market, projected to reach $150 billion in the next decade. The company, along with rivals like Eli Lilly, plans to launch its weight-loss therapies in India to meet the increasing demand for effective weight management solutions.